OverviewSuggest Edit

Jounce Therapeutics is a clinical-stage immunotherapy company. It develops cancer treatment therapies. It provides the translational science platform that identifies biomarkers to match the right therapy. 
TypePublic
Founded2013
HQCambridge, MA, US
Websitejouncetx.com
Employee Ratings4.4

Latest Updates

Employees (est.) (Dec 2019)130(+3%)
Job Openings15
Share Price (Oct 2021)$9
Cybersecurity ratingBMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Jounce Therapeutics

Stephen Farrand

Stephen Farrand

Chief Technical Officer
Richard Murray

Richard Murray

Chief Executive Officer and President, Director
Robert Kamen

Robert Kamen

Director
Elizabeth Trehu

Elizabeth Trehu

Chief Medical Officer
Hugh Cole

Hugh Cole

Chief Business Officer and Head of Corporate Development
Perry Karsen

Perry Karsen

Chairman
Show more

Jounce Therapeutics Office Locations

Jounce Therapeutics has an office in Cambridge
Cambridge, MA, US (HQ)
780 Memorial Dr
Show all (1)

Jounce Therapeutics Financials and Metrics

Jounce Therapeutics Revenue

USD

Net income (Q1, 2021)

(26.5m)

EBIT (Q1, 2021)

(26.6m)

Market capitalization (22-Oct-2021)

460.9m

Closing stock price (22-Oct-2021)

9.0

Cash (31-Mar-2021)

196.3m

EV

280.8m
Jounce Therapeutics's current market capitalization is $460.9 m.
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

General and administrative expense

23.1m26.4m27.9m28.8m

R&D expense

67.8m70.1m67.1m78.7m

Operating expense total

90.9m96.5m95.1m107.5m

EBIT

(19.2m)(31.3m)52.8m(45.1m)
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q3, 2020Q1, 2021

General and administrative expense

5.6m6.1m5.4m6.8m6.5m6.5m7.2m7.3m6.5m7.5m7.1m7.6m

R&D expense

15.0m17.2m17.1m18.2m18.5m16.8m17.3m18.1m15.1m19.6m18.0m20.5m

Operating expense total

20.5m23.3m22.5m25.0m25.0m23.3m24.5m25.5m21.6m27.2m25.1m28.1m

EBIT

(247.0k)(3.0m)(4.4m)(13.8m)(5.6m)(8.7m)(13.5m)(8.0m)97.8m(27.2m)(25.1m)(26.6m)
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

23.6m47.9m53.2m147.5m

Prepaid Expenses

19.9m2.3m4.9m4.9m

Current Assets

255.6m192.2m173.7m211.4m

PP&E

16.2m13.5m10.7m7.3m
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(16.4m)(27.4m)56.8m(43.8m)

Depreciation and Amortization

3.4m

Accounts Payable

373.0k562.0k(944.0k)(296.0k)

Cash From Operating Activities

(90.7m)(63.6m)(30.1m)(27.8m)
Quarterly
USDQ1, 2017

Financial Leverage

2 x
Show all financial metrics

Jounce Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

B

89/100

SecurityScorecard logo

Jounce Therapeutics Online and Social Media Presence

Embed Graph

Jounce Therapeutics News and Updates

Thinking about buying stock in BIO-key, AIM ImmunoTech, Jounce Therapeutics, Delta Air Lines, or Rekor Systems?

NEW YORK, Sept. 21, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BKYI, AIM, JNCE, DAL, and REKR. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Jounce Therapeutics Appoints Jigar Raythatha to its Board of Directors

CAMBRIDGE, Mass., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (Nasdaq: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced the appointment of former chief executive officer of Constella…

Jounce Therapeutics Reports Second Quarter 2021 Financial Results

- INNATE monotherapy dose escalation enrollment completed and target dose selected, on track to initiate indication specific expansions in third quarter 2021-

Jounce Therapeutics to Announce Second Quarter 2021 Financial Results and Host a Conference Call on Thursday, August 5, 2021

CAMBRIDGE, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report second quarter 2021 financial results and p…

Jounce Therapeutics to Participate in William Blair’s Biotech Focus Conference

CAMBRIDGE, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Dmitri Wiederschain, Ph.D., Chief Scientific Officer will …
Show more

Jounce Therapeutics Blogs

Jounce Therapeutics Announces Closing of Public Offering and Full Exercise of Over-Allotment Option

CAMBRIDGE, Mass., March 12, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (Nasdaq: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced the closing of its previously announced underwritten public

Jounce Therapeutics to Present Preclinical Data from JTX-8064 Program at the 2021 American Association for Cancer Research Virtual (AACR) Annual Meeting

CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that preclinical data informing indication selection for the

Jounce Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results

- Commenced enrollment in both the Phase 1 INNATE trial of JTX-8064 (LILRB2 / ILT4) and the Phase 2 SELECT trial of Vopratelimab in combination with JTX-4014 - - Ended 2020 with $213.2 million in cash, cash equivalents and investments - - Company to host conference call and webcast today at 8:00 AM

Jounce Therapeutics Announces Initiation of Phase 1 INNATE Study of JTX-8064 (LILRB2/ILT4 Inhibitor) Monotherapy and PD-1 Inhibitor Combination Therapy in Patients with Advanced Solid Tumors

Jounce Therapeutics Announces Initiation of Phase 1 INNATE Study of JTX-8064 (LILRB2/ILT4 Inhibitor) Monotherapy and PD-1 Inhibitor Combination Therapy in Patients with Advanced Solid Tumors Content Import Wed, 01/13/2021 - 08:01 Jounce Therapeutics Announces Initiation of Phase 1 INNATE S…

Jounce Therapeutics to Participate in a Fireside Chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference

Jounce Therapeutics to Participate in a Fireside Chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference Content Import Wed, 11/25/2020 - 08:01 Jounce Therapeutics to Participate in a Fireside Chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference No…

Jounce Therapeutics to Participate in a Virtual Fireside Chat at Cowen 2020 IO Next Summit

Jounce Therapeutics to Participate in a Virtual Fireside Chat at Cowen 2020 IO Next Summit Content Import Mon, 11/09/2020 - 08:02 Jounce Therapeutics to Participate in a Virtual Fireside Chat at Cowen 2020 IO Next Summit November 9, 2020 at 8:00 AM EST This re…
Show more

Jounce Therapeutics Frequently Asked Questions

  • When was Jounce Therapeutics founded?

    Jounce Therapeutics was founded in 2013.

  • Who are Jounce Therapeutics key executives?

    Jounce Therapeutics's key executives are Stephen Farrand, Richard Murray and Robert Kamen.

  • How many employees does Jounce Therapeutics have?

    Jounce Therapeutics has 130 employees.

  • Who are Jounce Therapeutics competitors?

    Competitors of Jounce Therapeutics include Personalis, Lyell and Triumvira.

  • Where is Jounce Therapeutics headquarters?

    Jounce Therapeutics headquarters is located at 780 Memorial Dr, Cambridge.

  • Where are Jounce Therapeutics offices?

    Jounce Therapeutics has an office in Cambridge.

  • How many offices does Jounce Therapeutics have?

    Jounce Therapeutics has 1 office.